|
1- An innovative approach in the field of biogeneric therapeutic products. Viropro provides pharmaceutical companies from emerging countries access to a new biotechnological platform allowing these companies to manufacture and bring to market biological therapeutic products at a competitive price.
|
|
2- A build-up of valuable worldwide exclusive rights.
|
|
3- A build-up of valuable worldwide exclusive rights.
|
|
4- The company expects to generate short to mid-term revenues from its rights, development and technology transfer expertise and long term recurring revenues from royalties on net sales made by its commercial partners related to biological therapeutic products.
|
|
5- Viropro intends to maintain a light, flexible and low overhead cost structure by out-sourcing services for non-core business activities.
|
|
6- Viropro is positioning itself in a market worth US$ 24 billion per year for the 10 biggest selling non-patented products for the treatment of diseases such as cancer, diabetes, chronic hepatitis and multiple sclerosis.
|
|
7- Viropro is entering this vital market with a solid technological platform and partnerships with local and international prominent players in product/process development.
|
